1H22 Financial Performance

Business sector update Medical Device Pharma Packaging 50.9% Revenue 35.4% Profit 15.1% Revenue 26.9% Profit Orthopedic Product 15.6% Revenue 26.6% Profit ❖ Achieved 19.0% y-o-y segment revenue growth in the first half of the year ✰ Volume-based procurement of various products in various provinces is actively advancing, the Company is seizing opportunities to rapidly increase sales ❖ Accelerated the progress of R&D, obtained 8 new Class III registration certificates, and continued to enrich the product portfolio Interventional Product ❖ Prefilled syringe revenue grew more than 20%. Industry influence is further enhanced ✰ International logistics complex led to delays in equipment production, but capacity expansion plans remained unaffected as a whole ❖ Sales teams follow up and serve over 90% innovative injection projects in China, capturing the biotech industry opportunity Blood Management The volume-based procurement of joint products has been carried out successively nationwide with sales growing rapidly ❖ Seized the opportunity of volum-based procurement in China, quickly filled in the white space in the hospital market, seized market share, further consolidated the market position in spine segment, and enhanced the all-round market competitiveness of joints, trauma, sports medicine and regenerative medicine Blood Purification (Not consolidated) 11.3% Revenue 5.3% Profit 7.0% Revenue 5.8% Profit Impacted by the supply chain issue, the delivery of some orders of Argon has been delayed, affecting the growth rate, but the situation has gradually recovered Through management improvement and cost optimization, segment profit margin continued to increase Although Argon China's business was affected by the COVID pandemic in Shanghai, it still grew rapidly. By continuous internal resource sharing, its market share in China increased WEGO威高 Through external cooperation and internal R&D, the Company continued to improve the product portfolio in the field of blood collection equipment and consumables Expanded the application scenarios of blood irradiators and promoted the application of the scientific research market Sorted out and strategically planned development opportunities in the blood product supply chain, cell therapy and stem cell fields In the first half of the year, Weigao Blood Purification completed a pre-IPO financing of nearly RMB1.5bn, led by well-known investors by way of capital injection and equity transfer ❖ Submitted a prospectus on the Hong Kong Stock Exchange in June this year 4

View entire presentation